Cabaletta Bio, Inc. (CABA) 株式分析

企業概要

Cabaletta Bio, Inc. is a clinical-stage biotechnology enterprise dedicated to the discovery and development of engineered T cell therapies designed to treat patients suffering from autoimmune diseases. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on extensive research and development cycles to bring novel therapeutics to market. As of the latest available data, the firm holds a market capitalization of 3.5289 億ドル (352.89M USD) and employs a workforce of 154 名。The absence of reported annual revenue figures in the current dataset indicates that the company is in a pre-revenue or early revenue stage typical of clinical-stage biotechs, where capital is primarily allocated toward advancing product candidates through clinical trials rather than generating commercial sales. This valuation metric, combined with the modest employee count, suggests the company remains in a growth-oriented phase where its market position is defined by its pipeline potential and intellectual property assets rather than established commercial cash flows.

財務健全性

The financial statements for the trailing twelve months report a net income of -1.67856 億ドル (-167,856,000 USD) and an EBITDA of -1.70595008 億ドル (-170,595,008 USD), while revenue is listed as unavailable (N/A). The significant gap between reported net income and EBITDA, alongside the lack of revenue data, reveals a cost structure dominated by high operating expenses such as research, development, and general administrative costs typical of the biotechnology sector, where revenue has not yet covered these expenditures. Free cash flow stands at -81,283,128 ドル，indicating that the company is currently burning cash to fund its operations and clinical programs, which limits immediate financial flexibility but is a common characteristic of companies in the clinical development stage. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet achieved profitability or that revenue is insufficient to calculate meaningful margins in the current reporting period. On the balance sheet, the company holds cash assets of 1.3360 億ドル against total debt of 2710 万ドル，resulting in a debt-to-equity ratio of 24.18, which suggests a balance sheet structure that relies heavily on equity financing rather than debt leverage to fund its expansion. The current ratio is 2.77, indicating a robust short-term liquidity position where current assets are nearly three times the value of current liabilities, providing a comfortable buffer against short-term obligations despite the negative cash flow. Furthermore, the return on equity (ROE) is -127.0% and the return on assets (ROA) is -61.5%, metrics that mathematically reflect the substantial net losses relative to the company's equity and asset base, signaling that management effectiveness is currently measured by the preservation of capital and the progression of the clinical pipeline rather than profit generation.

バリュエーション評価

Valuation multiples for Cabaletta Bio are presented with distinct characteristics due to its pre-profit status, as the trailing P/E ratio is N/A and the forward P/E is -2.26. The negative forward P/E implies that the market is pricing in future earnings growth that is expected to turn positive, although the specific trajectory remains unproven at this stage. The price-to-book ratio stands at 2.84, indicating that the market values the company at a premium of roughly 184% over its book value, which often reflects the intangible value of the clinical pipeline and intellectual property that is not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A and the EV/EBITDA is -1.44, suggesting that traditional valuation models based on sales or earnings multiples are not applicable in their conventional form and that investors must rely on asset-backed or pipeline-specific valuation methodologies. The stock's price has ranged between a 52-week low of 1.01 ドル and a 52-week high of 3.78 ドル，with the current trading position sitting dynamically within this range, subject to daily market fluctuations. The beta value is 3.29, which indicates that the stock's price volatility is significantly higher than the broader market, moving with approximately 3.29 times the magnitude of market swings, thereby presenting a higher risk profile for investors seeking stability compared to large-cap equities.

Growth & Income

Reported revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient revenue to calculate year-over-year percentage changes in the current dataset. In the absence of revenue history, it is impossible to determine whether earnings are growing faster or slower than revenue, as the primary driver of growth for a clinical-stage company is the successful advancement of its lead product candidate, resecabtagene autoleucel, through clinical trials. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that instead of distributing income to shareholders, the firm retains all earnings (or in this case, absorbs losses) to reinvest into research and development activities. Consequently, the overall growth and income profile for Cabaletta Bio, Inc. is characterized by a reinvestment strategy focused on clinical progression and product development, with no current income distribution to shareholders.